Patents by Inventor Emily Hanan
Emily Hanan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11760753Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: October 20, 2020Date of Patent: September 19, 2023Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Publication number: 20220389020Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: January 14, 2022Publication date: December 8, 2022Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20210246129Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: October 20, 2020Publication date: August 12, 2021Applicant: Genentech, Inc.Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. STABEN, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
-
Patent number: 10851091Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: September 24, 2018Date of Patent: December 1, 2020Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum Macleod, Richard Elliott
-
Publication number: 20200002345Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: September 5, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Patent number: 10435414Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: July 25, 2018Date of Patent: October 8, 2019Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Publication number: 20190263793Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: September 24, 2018Publication date: August 29, 2019Applicant: Genentech, Inc.Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. STABEN, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
-
Publication number: 20180327420Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: July 25, 2018Publication date: November 15, 2018Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Patent number: 10112932Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.Type: GrantFiled: October 10, 2017Date of Patent: October 30, 2018Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Patent number: 10065970Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: September 7, 2016Date of Patent: September 4, 2018Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Publication number: 20180162873Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: September 7, 2016Publication date: June 14, 2018Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Publication number: 20180127404Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.Type: ApplicationFiled: October 10, 2017Publication date: May 10, 2018Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Patent number: 9951064Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: GrantFiled: May 12, 2016Date of Patent: April 24, 2018Assignee: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Francois Diederich, Jennafer Dotson, Emily Hanan, Timothy Heffron, Michael Lainchbury, Robert Heald, Eileen M. Seward
-
Publication number: 20180065983Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: September 7, 2016Publication date: March 8, 2018Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
-
Patent number: 9890152Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.Type: GrantFiled: June 19, 2015Date of Patent: February 13, 2018Assignee: GENENTECH, INC.Inventors: Marian C. Bryan, Bryan Chan, Emily Hanan, Timothy Heffron, Hans Purkey, Richard Leonard Elliott, Robert Heald, Jamie Knight, Michael Lainchbury, Eileen M. Seward
-
Publication number: 20170283424Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: June 20, 2017Publication date: October 5, 2017Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20170210733Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.Type: ApplicationFiled: April 7, 2017Publication date: July 27, 2017Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Patent number: 9650393Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: July 1, 2016Date of Patent: May 16, 2017Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Patent number: 9643980Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: GrantFiled: July 1, 2016Date of Patent: May 9, 2017Assignee: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
-
Publication number: 20170015678Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.Type: ApplicationFiled: July 1, 2016Publication date: January 19, 2017Applicant: Genentech, Inc.Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott